EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

Jinjin Li, Wentong Wu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Xiaochun Yang, Hao Yan, Peihua Luo iD

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfae129 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Jinjin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Chin…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, ras Proteins, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The RAS gene family holds a central position in controlling key cellular activities such as migration, survival, metabolism, and other vital biological processes. The activation of RAS signaling cascades is instrumental in the development of various cancers. Although several RAS inhibitors have gained approval from the US Food and Drug Administration for their substantial antitumor effects, their widespread and severe adverse reactions significantly curtail their practical usage in the clinic. Thus, there exists a pressing need for a comprehensive understanding of these adverse events, ensuring the clinical safety of RAS inhibitors through the establishment of precise management guidelines, suitable intermittent dosing schedules, and innovative combination regimens. This review centers on the evolution of RAS inhibitors in cancer therapy, delving into the common adverse effects associated with these inhibitors, their underlying mechanisms, and the potential strategies for mitigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic Agentsras ProteinsMutationHumansAnimalsDrug ApprovalSignal TransductionDrugs, InvestigationalDrug Development

Stichwörter der Autor:innen

RASinhibitorsmanagementmechanismtoxicity

Substanzen

Antineoplastic Agentsras ProteinsDrugs, Investigational

Autor:innen und Institutionen

  • Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • School of Medicine, Hangzhou City University, Hangzhou 310015, China.
  • Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou 310018, China.
  • Nanhu Brain-Computer Interface Institute, Hangzhou 311100, China.
  • Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310018, China.

ORCID-Profile: Peihua Luo

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, J., Wu, W., Chen, J., Xu, Z., Yang, B., He, Q., Yang, X., Yan, H., & Luo, P. (2024). Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae129

Vancouver

Li J, Wu W, Chen J, Xu Z, Yang B, He Q, et al. Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae129

BibTeX
@article{Li2024,
  author = {Li, Jinjin and Wu, Wentong and Chen, Jiajia and Xu, Zhifei and Yang, Bo and He, Qiaojun and Yang, Xiaochun and Yan, Hao and Luo, Peihua},
  title = {Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfae129}
}
Kostenlos starten →